Bovie Medical Corporation Announces FDA Submission Of Laparoscopic Device For Solid Organ Resection

Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, announced a 510K submission to the FDA seeking pre-market clearance for a laparoscopic SEER device for solid organ resection. The laparoscopic SEER is a line extension of the Saline Enhance Electrosurgical Resection (SEER) device that Bovie launched earlier this year and will address the growing market of minimally invasive liver resection.

The laparoscopic SEER allows the surgeon to dissect and achieve hemostasis with a single device resulting in less instrument utilization and fewer instrument changes in a minimally invasive approach. The laparoscopic SEER is the second developed product in a series of new products under development based on the sintered steel technology.

Andrew Makrides, president of Bovie, stated, “Surgeons response to the SEER has been very positive and this new device will allow us to address their requests for a laparoscopic version.”

Bovie Medical Corporation

This entry was posted in Uncategorized. Bookmark the permalink.